PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist developed from Melanotan II. Actively investigated in sexual health research, PT-141 is studied for its central nervous system mediated activation of MC3R and MC4R pathways to regulate sexual response.

"Unlike traditional vascular agents, Bremelanotide PT-141 operates centrally via melanocortin pathways in the brain to research sexual drive pathways."

Detailed clinical evaluation records are cataloged at the ClinicalTrials.gov Bremelanotide Database and peer-reviewed papers are searchable at PubMed PT-141 Registry for academic review. Structural biochemistry records are hosted at the PubChem PT-141 Portal.

Key Areas of Investigation:

• Central Melanocortin Pathway Agonism: Evaluating MC3R and MC4R binding kinetics in cortical assays.
• Neurogenic Arousal Mechanisms: Preclinical studies on copulatory behavior in animal models.
• Systemic Vascular Stability: Studies on blood pressure parameters in response to exposure.

This material is supplied exclusively as a lyophilized solid for laboratory research and analytical evaluation, and is strictly not for human or therapeutic use.